Outsourcing Outlook

The Biotechnology Industry Organization lends insight into the trends of biopharmaceutical contract manufacturing.

This second annual survey tracks teh growth of the outsourcing services sector in the past year.

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Gene Logic acquires TherImmune Research Corp. as part of its plan to create a new business model; First quarter results are a mixed bag for contract services companies.

The successful auction of Quintiles raises questions for the company's new owners, Pharma Services Holdings, Inc., and the entire pharmaceutical industry with regard to strategic investments, assets to be sold, and other concerns.

As demand for contract services slows down, contractors restructure themselves and the industry.

CROs and CMOs project strong business operation in 2003, and contract sterile manufacturing companies invest millions to increase capacity.

A column covering the outsourcing industry.

Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.

December's Contract Services articles include "Using Virtual Private Networks to Gain Competitive Advantage," by Mark Tuomenoska and "Outsourcing Outlook," by Jim Miller.

November's Contract Services articles include "Outsourcing Xbox Manufacturing," by Heather Hayes, "Outsourcing Outlook," by Jim Miller, and "Quality in Pharmacovigilance," by Brian Edwards and Jeffrey Priem.

The European Union is attempting to reform its current business environment in hopes of restoring its role in the lobal R&D sector.

The author discusses the potential effect on CROs of pending major-pharma mergers and consolidations.

The author examines the concept of evaluating CRO operating performance in today's pharmaceutical industry.

The results of this 2002 survey of contract services decision makers reviews and forecasts the state of the outsourcing industry.

The author discusses the Japanese cabinet's approval of a measure that lifts manufacturing restrictions on domestic pharmaceutical companies.

The author discusses the upcoming human research congressional debate and CROs' preparations to respond.

A knowledgeable and experienced contract service provider can help in the development and success of an inhalation drug product.

The author discusses recent acquisition activity in the chemistry, manufacturing, and controls (CMC) outsourcing industry.

The author discusses the current soft demand and excess capacity in the contract-manufacturing market of small molecule actives and intermediates.

The author discusses three current examples of new ideas in formulating outsourcing arrangments.

Public CROs are creating new ways of operating their outsourcing businesses to remain competitive in difficult economic conditions.

The author discusses current economic times and conditions for large pharmaceutical companies.

The author looks ahead to what 2002 may have in store for the contract services industry.

CROs must take advantage of Internet-based technologies to remain competitive and relevant in the industry.

Capacity is a pivotal commodity in the contract manufacturing business. If you have enough of the right kind of capacity, it's like platinum; conversely, too much of the wrong kind of capacity is like tin.

The 2001 POMA Sourcing Survey declares 2001 a good year for drug development and manufacturing outsourcing.

Recovery of the contract services industry picked up steam in the quarter ending 30 June 2001.

Evaluating a CRO should involve acquiring feedback from various personnel within the CRO, ranging from executives to line workers.

This project­based quality­improvement program uses short­term goals to achieve the long­term objectives of constant, continuous improvement.